Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
Executive Summary
The Arthritis Drugs Advisory Committee's negative review of Merck's Arcoxia could be more indicative of the increasingly challenging regulatory environment for "me too" products than concerns over the Vioxx follow-on's safety profile